Form 4: Madrigal Pharmaceuticals Director Kenneth Bate Receives Significant Equity Awards

Madrigal Pharmaceuticals, Inc. Director Kenneth Bate was granted 715 restricted stock units and 1,290 stock options on June 20, 2025, as part of his compensation package.

Summary

• Kenneth Bate, a Director of Madrigal Pharmaceuticals, Inc. (MDGL), received equity awards on June 20, 2025.
• The awards include 715 shares of Common Stock in the form of Restricted Stock Units (RSUs), granted at a price of $0.
• These RSUs are scheduled to vest on the date of the Issuer's annual meeting of stockholders in 2026, contingent on Mr. Bate's continued service.
• Additionally, Mr. Bate was granted 1,290 stock options with an exercise price of $285.73, also granted at a price of $0.
• These stock options will vest 100% on the date of the Issuer's annual meeting of stockholders in 2026, provided he continues to serve as a director until that date.
• The stock options have an expiration date of June 20, 2035.
• Following these transactions, Mr. Bate beneficially owns 2,627 shares of Common Stock and 1,290 stock options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The grant of equity awards to a director is a standard practice that aligns the director's interests with the company's long-term performance, which is generally viewed favorably. It indicates continued commitment from the director.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with those of shareholders, incentivizing long-term performance and value creation.
• The equity awards serve as a form of compensation for the director's continued service, reinforcing commitment to Madrigal Pharmaceuticals.

Negatives

• The issuance of new equity awards, particularly stock options, can lead to minor dilution for existing shareholders if the options are exercised in the future.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon Kenneth Bate's continued service as a director until the Issuer's annual meeting of stockholders in 2026. If his service ceases before this date, the awards may be forfeited.

Future Outlook

The vesting of the granted restricted stock units and stock options is contingent upon the director's continued service until the Issuer's annual meeting of stockholders in 2026, indicating an expectation of ongoing commitment from the director.

Industry Context

SEC Form 4 filings are routine disclosures of insider trading activity, providing transparency into transactions by company directors, officers, and significant shareholders. This specific filing indicates a standard equity grant to a director as part of their compensation package, a common practice across industries to align management incentives with shareholder interests.

Comparison to Industry Standards

• This type of equity grant (RSUs and stock options with vesting conditions) is a standard component of director compensation packages in the biotechnology and pharmaceutical industries.
• Similar practices are observed at peer companies of similar market capitalization and stage of development, such as Regeneron Pharmaceuticals, Inc. (REGN) or Vertex Pharmaceuticals Incorporated (VRTX), which frequently use equity to incentivize long-term commitment and performance from their board members.
• The specific value and number of units granted would typically be benchmarked against industry peers, though this document does not provide comparative data for a direct assessment of the grant's size relative to industry averages.

Related Party Transactions

• The grant of restricted stock units and stock options to Kenneth Bate, a director of Madrigal Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term decision-making. However, the issuance of new shares upon vesting or exercise could result in minor dilution.
• Employees: While not directly impacted, such compensation practices can set precedents for executive and director remuneration within the company.

Next Steps

• The restricted stock units and stock options are scheduled to vest on the date of Madrigal Pharmaceuticals' annual meeting of stockholders in 2026.
• Kenneth Bate must continue in service as a director until the vesting date for the awards to be realized.
• The stock options will expire on June 20, 2035.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership